Gopika Ashokan

Ms. Gopika Ashokan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ACAdana-Christine Campbell
Adana-Christine Campbell
JBJung Eun Baik
Jung Eun Baik
ASAnanta Sarker
Ananta Sarker
SBStav Brown
Stav Brown
HPHyeung Ju Park
Hyeung Ju Park
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara

24 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
BPBracha L. Pollack
Bracha L. Pollack
JTJeremy S. Torrisi
Jeremy S. Torrisi
GHGeoffrey E. Hespe
Geoffrey E. Hespe
GAGopika Ashokan
Gopika Ashokan
JSJinyeon Shin
Jinyeon Shin
RKRaghu P Kataru
Raghu P Kataru
Background/Objectives: Chronic wounds pose a significant healthcare burden, and there remains no effective animal model for study. We aimed to develop a mouse model of chronic wounds that remain open for at least 4 weeks and to investigate the role of the lymphatic system in wound healing. Methods: Full-thickness excisional wounds were created on the dorsal surface of mouse tails to simulate chronic wounds. Lymphatic drainage was assessed using FITC–dextran lymphangiography. Histology and immunofluorescence were used to analyze immune cell infiltration. The effect of inhibiting Th2 differentiation via IL-4 and IL-13 neutralization on wound closure was also evaluated. Results: Our chronic wound model was successful, and wounds remained open for 4 weeks. Impaired lymphatic drainage was observed extending beyond the wound area. Increased CD4+ T-helper cell infiltration and Th2 cell accumulation were observed in the impaired lymphatic drainage zone. Inhibition of IL-4 and IL-13 accelerated wound healing. Conclusions: Impaired lymphatic drainage and Th2-mediated inflammation contribute to delayed healing, and gradients of lymphatic fluid flow are associated with spatial differences in lymphangiogenesis. Targeting Th2 cytokines may offer a novel therapeutic approach for chronic wounds.

30 March 2026 in JID Innovations
Verified
Journal Article
Open access
XCXizhao Chen
Xizhao Chen
KKKevin Kuonqui
Kevin Kuonqui
SPSarit Pal
Sarit Pal
JSJinyeon Shin
Jinyeon Shin
ASAnnica Stull-Lane
Annica Stull-Lane
RKRaghu P Kataru
Raghu P Kataru
Keratinocytes, once viewed as inert epidermal scaffolds, are now recognized as active participants in the cutaneous immunity. They orchestrate local immune responses by releasing cytokines, chemokines, and alarmins that shape innate and adaptive inflammation. Dysregulated keratinocyte-immune interactions underline chronic inflammatory skin disorders, such as atopic dermatitis, psoriasis, and cutaneous lupus erythematosus. More recently, keratinocytes have been identified as key contributors to secondary lymphedema, a chronic inflammatory and fibrotic condition historically attributed to lymphatic dysfunction. This review revises our understanding of keratinocytes as immunomodulatory cells, while focusing primarily on their emerging role in the pathogenesis of secondary lymphedema. We highlight and appraise recent evidence that lymphatic stasis reprograms keratinocyte differentiation, induces type 2 helper T cells-skewed inflammatory responses, and perpetuates chronic inflammation and fibrosis. Understanding this keratinocyte-immune-lymphatic axis may unveil novel therapeutic targets beyond traditional lymphangiogenic approaches.

31 July 2026 in Skin Health and Disease
Verified
Journal Article
Open access
BPBracha L Pollack
Bracha L Pollack
ARArielle N Roberts
Arielle N Roberts
BWBenjamin D Wagner
Benjamin D Wagner
GAGopika Ashokan
Gopika Ashokan
XCXizhao Chen
Xizhao Chen
RKRaghu P Kataru
Raghu P Kataru
T helper type 2 (Th2)-mediated inflammatory skin diseases, including atopic dermatitis, discoid lupus erythematosus, systemic sclerosis, autoimmune bullous diseases and secondary lymphoedema, demonstrate significant racial and ethnic disparities in prevalence, severity and clinical outcomes. These disorders share pathogenic mechanisms involving Th2-driven immune activation, fibrosis and epidermal barrier dysfunction, leading to chronic inflammation and substantial morbidity. Black and Hispanic populations consistently experience greater disease burden, more severe clinical manifestations and reduced quality of life compared with White patients, reflecting complex interactions between biologic and socioeconomic factors. Current molecular and immunological studies suggest that ancestry-associated differences in immune polarization, cytokine signalling, autoantibody expression, fibrotic pathways and epidermal barrier biology may contribute to variation in disease phenotype and severity across Th2-mediated disorders. Black patients have demonstrated enhanced Th2 and Th22-mediated inflammation, increased IgE production, elevated interleukin (IL)-4, IL-13 and IL-22 signalling, and distinct genetic and serological profiles, including variation in filaggrin-related barrier proteins and autoantibody expression. However, mechanistic studies directly evaluating race-associated Th2 immune responses remain limited in many inflammatory skin diseases, and under-representation of diverse populations in translational research and clinical trials continues to restrict understanding of disease biology and therapeutic response. This review synthesizes the current epidemiological, molecular and immunological evidence linking race, immune dysregulation and disease heterogeneity across Th2-mediated skin disorders. Together, these findings support a growing framework in which ancestry-associated differences in immune regulation and social determinants jointly shape disparities in Th2-mediated inflammatory skin disease.